 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

ALPHARETTA, Ga., April 02, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through...

Clearside Biomedical to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference

Clearside Biomedical, Inc. (NASDAQ:CLSD  Free Report)  Analysts at Wedbush issued their Q1 2024 EPS estimates for shares of Clearside Biomedical in a research note issued on Wednesday...

Clearside Biomedical, Inc. to Post Q1 2024 Earnings of ($0.12) Per Share, Wedbush Forecasts (NASDAQ:CLSD)

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Clearside Biomedical appoints Chong as Chief Medical Officer

Industry Veteran with Extensive Experience in Retinal Disease Research and Strong Track Record in Advancing Programs Through Clinical Development
 Victor Chong, M.D., MBA

 Victor...

Clearside Biomedical Appoints Victor Chong, M.D., MBA as Chief Medical Officer

Wedbush restated their outperform rating on shares of Clearside Biomedical (NASDAQ:CLSD  Free Report) in a report released on Wednesday morning, RTT News reports. The firm currently has a...

Clearside Biomedical (NASDAQ:CLSD) Stock Rating Reaffirmed by Wedbush

Q4 2023 Clearside Biomedical Inc Earnings Call Transcript

Licensing Deals Propel Revenue as Company Advances Clinical TrialsRelated Stocks: CLSD...

Clearside Biomedical Inc (CLSD) Reports Significant Licensing Revenue Growth in Q4 and Full ...

Clearside Biomedical: Q4 Earnings Insights

- Phase 2b ODYSSEY Wet AMD Trial Remains on Track with Topline Data Expected in Q3 2024 - - Partner Programs Continue to Report Positive Clinical Data Utilizing SCS Microinjector - - Strengthened...

Clearside Biomedical Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Clearside Biomedical, Inc. (NASDAQ:CLSD  Get Free Report) has been given an average recommendation of Buy by the four analysts that are presently covering the firm, Marketbeat...

Brokerages Set Clearside Biomedical, Inc. (NASDAQ:CLSD) Price Target at $5.00

Clearside Biomedical, Inc. is a biopharmaceutical company, which delivers therapies to the back of the eye through the suprachoroidal space. Its pipeline include CLS-AX, Integrin Inhibitor, and gene therapy. The company was founded by Samir Kumar Patel, Vladimir Zarnitsyn, Mark Prausnitz, Daniel H. White, and Henry F. Edelhauser in May 2011 and is headquartered in Alpharetta, GA.

Volume (M)	119,921.00
52-Wk High	$2.12
52-Wk Low	$0.6501

CLSD Clearside Biomedical Inc

About

Feed

News

Sentiment

Earnings

Fundamentals